We are pleased to announce that Dompé S.p.A. has entrusted Maxer Consulting with implementing the Clinical Trial Disclosure and Data Transparency (CTD/DT) program for 2023-24. CTD’s activities require Maxer to ensure compliance by Dompé with the regulations in force in the European Union (EU Reg. 536/2014) and the United States… read more →
Maxer is pleased to relaunch the article published by AboutPharma in the December 2022/January 2023 issue, entitled A data-driven method: following “traces” on the web helps to profile doctors. The article, written by Massimo Zaninelli, Laura Gatti, Marco Santagostino and Fausto Volonté, presents the method of profiling health professionals’ digital… read more →
We are pleased to announce that the Zambon Group has entrusted Maxer Consulting to implement the Clinical Trial Disclosure program for 2021. The program requires Maxer to carry out the necessary activities to ensure Zambon’s compliance with the regulations in force in the European Union (EU Reg. 536/2014) and the United… read more →
Massimo Zaninelli, Maxer Consulting CEO, has published on PharmaStar the article Clinical Trial Disclosure and Data Transparency: an obligation or opportunity? The publication of interventional clinical studies is mandatory both in the European Union and in the USA. The author intends to highlight the benefits that this activity offers to the… read more →
Maxer continues its collaboration with the IQVIA Italia Study Centre by editing the text of Farmaci biologici e biosimilari: scenari terapeutici e stima del risparmio per il Sistema Sanitario italiano. The essay analyses the evolution of the therapeutic scenarios following up the patent expiring of many originator drugs and its… read more →
In early 2017 Massimo Zaninelli will be teaching professor of Corporate Communication at the Master course Web communication & social media at the University Parma. Over the next weeks, we will inform you about the precise date of the beginning of the course. The Master, at its fifth edition, foresees… read more →
EMA recently published a press release on Clinical Trial Transparency . The text informs that, as of October 20, the Agency started the publication of the redacted clinical reports* of drugs with MAA submitted on or after January 1, 2015, * (or July 1, 201, for extensions/modifications of Indication /line extensions).** The website… read more →
